Abstract:Purpose: Separating mild from significant fibrosis is an important step in the decision making process in treating and evaluating the prognosis of HCV patients. Liver biopsy remains the gold standard. The APRI*. is a recently proposed index (Wai et al. Hepatology; 38:518–526) that we have found to be accurate in both a retrospective and prospective study of patients with HCV undergoing liver biopsy at our institution. Cutoffs of ≤0.42 and ≥1.2 accurately identified patients with mild and significant fibrosis (Snyder et al Gastroenterol 126:A-304, Snyder et al Am J Gastroenterol 99 S100–101). Rodríguez-Iñigo et al, found that the percentage of hepatocytes expressing Factor VII was significantly lower in stage 4 liver fibrosis patients than in stage 3, stage 2, stage 1 and stage 0 patients (P < 0.001). (Blood Coagulation & Fibrinolysis, 12:193). We hypothesized that addition of Facto VII measurement might enhance the sensitivity of the APRI. *APRI = AST/ULN × 100/platelets(109/L) Methods: The patients studied were 19 patients with chronic HCV undergoing pretreatment liver biopsies. Patients were excluded if they had received anti-viral treatment within the last year, if they were co infected with HBV or HIV, or had an organ transplants. All patients had blood drawn on the day of the biopsy. The Factor VII assay was run on the STA-R instrument (Diagnostic Stago Parsippany, NJ.) The APRI was calculated. The liver biopsies were read blindly by one pathologist using the Ludwig Batts criteria for staging of fibrosis. Analysis was performed using Insightful Miner 2 software (Insightful Corporation Seattle, WA.). Results: One patient had an inadequate biopsy and two other patients did not have Factor VII measured because of inadequate specimen. Based on the biopsy results, there were 13 patients with significant fibrosis (F2–F4) and 5 patients with mild fibrosis (F0–F1). By logistic regression, the APRI had a sensitivity of 84.6% and a specificity of 60%. The combination of the APRI and Factor VII resulted in an improved sensitivity of 100% and a specificity of 100% in separating patients with significant fibrosis from patients with mild fibrosis. Conclusions: Factor VII measurement may improve the sensitivity and the specificity of the APRI score in separating mild and significant fibrosis in patients with HCV. A larger number of patients is needed to evaluate this further.

Evaluation of the aspartate aminotransferase/platelet ratio index and enhanced liver fibrosis tests to detect significant fibrosis due to chronic hepatitis C.

Predictive Value of the Red Blood Cell Distribution Width-to-platelet Ratio for Hepatic Fibrosis.

APRI: an Easy and Validated Predictor of Hepatic Fibrosis in Chronic Hepatitis C.

The APRI may be enhanced by the use of the FIBROSpect II in the estimation of fibrosis in chronic hepatitis C.

Can We Predict the Degree of Fibrosis in Chronic Hepatitis C Patients Using Routine Blood Tests in Our Daily Practice?

Comparison of diagnostic accuracy of aspartate aminotransferase to platelet ratio index and fibrosis-4 index for detecting liver fibrosis in adult patients with chronic hepatitis B virus infection: a systemic review and meta-analysis.

Noninvasive Methods for Detecting Advanced Liver Fibrosis and Cirrhosis in Patients with Chronic Hepatitis B: A Single-Center Retrospective Study

Noninvasive Assessment of Liver Fibrosis with Combined Serum Aminotransferase/platelet Ratio Index and Hyaluronic Acid in Patients with Chronic Hepatitis B.

Diagnostic Accuracy of the Aspartate Aminotransferase-to-platelet Ratio Index for the Prediction of Hepatitis B-related Fibrosis: a Leading Meta-Analysis

Performance of the Aspartate Aminotransferase-to-platelet Ratio Index for the Staging of Hepatitis C-related Fibrosis: an Updated Meta-Analysis.

Combined Acoustic Radiation Force Impulse, Aminotransferase To Platelet Ratio Index And Forns Index Assessment For Hepatic Fibrosis Grading In Hepatitis B

Accuracy of transient elastography-FibroScan®, acoustic radiation force impulse (ARFI) imaging, the enhanced liver fibrosis (ELF) test, APRI, and the FIB-4 index compared with liver biopsy in patients with chronic hepatitis C

Retrospective Evaluation of Non-Invasive Assessment Based on Routine Laboratory Markers for Assessing Advanced Liver Fibrosis in Chronic Hepatitis B Patients

Plateletcrit As a Potential Index for Predicting Liver Fibrosis in Chronic Hepatitis B

Serum Markers for Predicting Advanced Fibrosis in Patients with Chronic Hepatitis B and Nonalcoholic Fatty Liver Disease.

Application of aspartate aminotransferase to cholinesterase ratio for predicting hepatic fibrosis in patients with chronic hepatitis B

Evaluation and comparison of the diagnostic performance of routine blood tests in predicting liver fibrosis in chronic hepatitis B infection.

The Apri is A Fair Estimator of Fibrosis in Nafld, and May Be Enhanced by the Use of Age

Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection

The gamma-glutamyl transpeptidase to albumin ratio predicts significant fibrosis and cirrhosis in chronic hepatitis B patients.

Plasma Factor VII May Increase the Sensitivity and Specifiicity of the APRI Score in Seperating Mild and Significant Fibrosis in Patients with Hepatitis C